Nuevolution AB (publ) Stock price

Equities

NUE

SE0007730650

Pharmaceuticals

Delayed Nasdaq Stockholm 5-day change 1st Jan Change
- SEK -.--% Intraday chart for Nuevolution AB (publ) -0.31% +90.59%

Financials

Sales 2017 9.65M 1.4M 14.93M Sales 2018 10.97M 1.59M 16.97M Capitalization 842M 122M 1.3B
Net income 2017 -123M -17.79M -190M Net income 2018 -99M -14.32M -153M EV / Sales 2017 62.2 x
Net cash position 2017 111M 16.07M 172M Net cash position 2018 108M 15.67M 168M EV / Sales 2018 66.9 x
P/E ratio 2017
-5.8 x
P/E ratio 2018
-7.98 x
Employees -
Yield 2017 *
-
Yield 2018
-
Free-Float 90.97%
More Fundamentals * Assessed data
Dynamic Chart
Amgen Inc. completed the acquisition of Nuevolution AB (OM:NUE) from Industrifonden, Skandinaviska Enskilda Banken AB (publ.) (OM:SEB A), Sunstone LSV Fund I K/S, SEB-Stiftelsen, Skandinaviska Enskilda Bankens Pensionsstiftelse, S-E-Bankens Utvecklingsstiftelse and others. CI
Nuevolution AB Reports Earnings Results for the First Quarter Ended of March 2019 CI
Amgen Inc. made an offer to acquire Nuevolution AB (OM:NUE) from Industrifonden, Skandinaviska Enskilda Banken AB (publ.) (OM:SEB A), Sunstone LSV Fund I K/S, SEB-Stiftelsen, Skandinaviska Enskilda Bankens Pensionsstiftelse, S-E-Bankens Utvecklingsstiftelse and others for SEK 1.6 billion. CI
Nuevolution's BET-BD1 Selective Inhibitor and Candidate Compound, NUE20798, Shows Positive Effect on Disease Scoring and Biomarker Levels in an Atopic Dermatitis Mouse Model CI
Nuevolution AB Announces Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2018 CI
Nuevolution AB Publ Reports Earnings Results for the Fourth Quarter Ended December 31, 2018 CI
Nuevolution AB Announces First Animal Preclinical Data CI
Nuevolution AB Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018 CI
Nuevolution to Present Data from its Discovery Program Directed at Targeting the Key Disease Inflammatory Signaling Molecule, Interleukin-17A (IL-17A) CI
Nuevolution AB Announces Executive Changes CI
Nuevolution AB Announces Consolidated and Parent Earnings Results for the Second Quarter and Six Months Ended June 30, 2018 CI
Nuevolution Discloses the Identity of Its Cytokine X Program Being Interleukin IL-17A CI
Amgen Exercises Opt-In Right in First Program from Multiple Target Research Collaboration with Nuevolution CI
Nuevolution AB(OM:NUE) added to OMX Nordic Small Cap Index CI
Nuevolution AB(OM:NUE) added to OMX Nordic All-Share Index CI
More news
Nuevolution AB is a Sweden-based biopharmaceutical company working to develop future medicine for the treatment of cancer and inflammatory diseases. The Company's business is conducted through its wholly owned subsidiary, Nuevolution A/S.
More about the company
  1. Stock
  2. Equities
  3. Stock Nuevolution AB (publ) - Nasdaq Stockholm